← Eichor
Study identifier: NCT07722780 Synced from ClinicalTrials.gov · July 28, 2026
● Not Yet Recruiting

Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE

Condition: Premature Ejaculation  ·  Sponsor: Vigonvita Life Sciences

PhasePhase 2
Planned participants500
Who can joinMale, 18 Years to 55 Years
Healthy volunteersNo

About this study

This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.

This description comes directly from the study's public registry record.

Talk to the study team

Huaqing Duan  ·  18061926005  ·  huaqing.duan@vigonvita.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University First HospitalBeijing, Beijing Municipality, China

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07722780